

SPHHP Research Activities Newsletter

University at Buffalo

May 2019


IN THE NEWS

Congratulations to the Following Awardees!



R. Lorraine Collins, Professor of Community Health and Health Behavior and Associate Dean for Research for SPHHP, is Co-I on two continuation awards. The first, from the National Institute on Alcohol Abuse and Alcoholism/NIH (PI: Maria Testa, Psychology) is entitled, *Alcohol, Self-Control, and Intimate Partner Aggression*. The study will continue to examine the temporal effects of within-day fluctuations in self-control, in combination with alcohol use, on partner aggression within couples' daily lives.

The second, from the National Institute on Alcohol Abuse and Alcoholism/NIH (PI: Ken Leonard, UB's Clinical and Research Institute on Addictions), is entitled, *Research Training on Alcohol Etiology and Treatment*. The award will continue to provide support for RIA's Postdoctoral Training Program. Established in 2000, the program provides six trainees with both general and individualized research training on the etiology and treatment of alcohol problems.



David Hostler, Professor and Chair of Exercise and Nutrition Sciences, is PI on two new awards from CREARE LLC. The projects, entitled *SBIR: Support for Non-Invasive Hydration Level Monitor* and *Hydration Level Monitor Human Subject Research*, will develop and test a prototype real-time hydration sensor for military pilots. If successful, this sensor would limit the amount of hypohydration on long missions, reduce thermal stress, and prevent decrements in performance. **Zachary Schlader**, Assistant Professor of Exercise and Nutrition Sciences, is Co-I.



Heather Ochs-Balcom, Associate Professor of Epidemiology and Environmental Health, is PI on a new award from the National Cancer Institute/NIH for the project entitled, *Genetic Epidemiology of Breast Cancer Disparities in Women of African Ancestry*. The study will analyze existing family- and population-based GWAS data in large-scale genetic studies to answer important questions about breast cancer disparities.



James Olson, UB Distinguished Professor of Pharmacology and Toxicology & Epidemiology and Environmental Health, is PI on a new award from the University of Iowa/NIH for the project entitled, *Vulnerability of the Adolescent Brain to Organophosphorus Pesticides*. The study will follow a cohort of male and female adolescents across multiple years to examine the impact of cumulative real-world pesticide exposure scenarios on neurobehavioral performance and evaluate an intervention to reduce exposure. **Matthew Bonner**, Associate Professor of Epidemiology & Environmental Health, is Co-I.



Todd Rideout, Associate Professor of Exercise and Nutrition Sciences, is PI on a new award from Pennsylvania State University/NIDDK for the project entitled, *Regulation of Skeletal Muscle Anabolic Resistance in Obesity*. The goal of the project is to reveal an innovative mechanism of anabolic action in skeletal muscle during obesity that could be targeted, resulting in new and innovative approaches to prevent and treat disorders exhibiting skeletal muscle anabolic resistance.

Inside this issue:

In the News	1-2
Grant Clinic	2
NIH Funding	
Limited Submissions	2-3
RFAs	3-7
PARs	7-8
PAS	8
NIDILRR	9
DOD	9-10
Words to Live By	10



Jihnhee Yu, Associate Professor of Biostatistics, is Co-I (PI: Hui Meng, Mechanical and Aerospace Engineering) on a continuation award from the National Institute of Neurological Disorders and Stroke/NIH for the project entitled, *Virtual Intervention of Intracranial Aneurysms*. The study will continue to develop a method of predicting treatment outcome of intracranial aneurysms with clinically-practical computational tools to simulate endovascular treatment strategies.

GRANT CLINIC

Complying with NIH Publication mandates.

A recent newsletter from UB's CTSI included important information about meeting the mandate from NIH (and other funders) to make research publications accessible. As noted in the item, "The NIH public access policy requires that all NIH-funded investigators submit an electronic version of their final published peer-reviewed manuscript to PubMed Central so that it can be included in its digital archive. This policy ensures that the public has access to the published NIH-funded research discoveries to advance science and improve health. Follow this link to learn more.

http://www.buffalo.edu/ctsi/ctsi-news.host.html/content/shared/www/ctsi/articles/academic_articles/public-access-to-important-research-findings-begins-with-the-investigator.detail.html

Webinar Series Provides Helpful Information for Interested Applicants to the Congressionally Directed Medical Research Programs (CDMRP)

The CDMRP presents a webinar series on types of funding opportunities offered and strategies to increase the success of applications submitted to different CDMRP programs. Some of the topics include: 1. *Funding Opportunities and Strategies for Success* (details how to find CDMRP funding opportunities, understand the process for applying, and identify tips for success as well as pitfalls in grant application design); 2. *High Risk/High Gain Funding Opportunities* (discusses the three categories of hypothesis-driven, high risk/high gain funding opportunities - Initial Concept Awards, Early Idea Awards, and Established Idea Awards); and 3) *Funding Opportunities for Early Career Investigators* (an overview of funding opportunities that target early career investigators and some of the unique criteria utilized in these funding opportunities). The full list of available webinars and the links to view can be found [here](#).

NIH NOTICES

[NOT-OD-19-099](#)

Guidance on Salary Limitation for Grants and Cooperative Agreements FY 2019

Effective January 6, 2019, the NIH salary limitation for Executive Level II is \$192,300. For awards that are restricted to previous Executive Level II limits, if adequate funds are available in active awards, and if the salary cap increase is consistent with the institutional base salary, grantees may rebudget to accommodate the current Executive Level II salary level. However, no additional funds will be provided to these grant awards.

[NOT-HD-19-006](#)

Request for Information: Research Plan on Rehabilitation

NICHD, National Center for Medical Rehabilitation Research, is inviting comments and suggestions to guide the revision of the Research Plan on Rehabilitation on behalf of the Trans NIM Medical Rehabilitation Coordinating Committee. Please refer to the NIH notice for topics requesting feedback. Responses are limited to 300 words (MS Word or PDF format) and must be submitted electronically to Rehabilitation1@mail.nih.gov by **June 17, 2019**.

Notices of Intent to Publish a Funding Opportunity Announcement

[NOT-OD-19-104](#)

Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21) – clinical trial not allowed; anticipated release August 2019; expected due date October 8, 2019

NIH FUNDING OPPORTUNITIES

LIMITED SUBMISSIONS

Prior approval from UB is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. The limited submission program is managed by Dr. Kenneth Tramposch on behalf of the OVPRED. He may be contacted at kmt1@buffalo.edu or by phone at 645-3321 for any questions or advice about the limited submission process.

[RFA-DK-18-020 \(P30\)](#)

Diabetes Research Centers

This FOA invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org. *Only one application per institution is allowed.* **Application Due Date:** June 20, 2019

[RFA-DK-19-002 \(P30\)](#) – clinical trial optional

Nutrition Obesity Research Centers (NORCs)

The mission of the NORC program is to serve as a key component of the NIDDK-supported research effort to advance nutrition and obesity research. The NORCs promote new discoveries and enhance scientific progress through support of cutting-edge basic, clinical, and translational research in nutrition science and obesity with the ultimate goal of improving public health. *Only one application per institute is allowed.* **Application Due Date:** October 23, 2019

NIH FUNDING OPPORTUNITIES

REQUESTS FOR APPLICATIONS (RFA)

June Due Dates

[RFA-ES-19-007 \(R35\)](#) – clinical trial not allowed; [RFA-ES-19-008](#) (basic experimental studies with humans required)

Revolutionizing Innovative, Visionary Environmental Health Research (RIVER)

The RIVER program is intended to fund people rather than projects; rewarding outstanding Environmental Health Sciences researchers who demonstrate a broad vision and potential for continuing their impactful research with increased scientific flexibility, stability in funding, and administrative efficiency. It is felt that these scientists can demonstrate an outstanding record of creative research at any career stage and RIVER seeks to identify investigators at mid-career stages as well as more established investigators. **Application Due Date:** June 20, 2019

[RFA-HD-20-004 \(P2C\)](#) – clinical trial optional

Medical Rehabilitation Research Resource

The aim of this FOA is to create a national network of research centers that provide access to collateral expertise in biomedical, behavioral, engineering, and/or psychosocial fields that are particularly relevant to medical rehabilitation research and the needs of people with chronic physical disabilities. Specifically, the NIH is interested in addressing gaps in the rehabilitation research portfolio and is particularly interested in the following high-priority areas: pediatric rehabilitation; personalized medicine approaches; family, caregiver, and community support; implementation and dissemination research; clinical trial design; strategies to explore and validate combination therapies; and, technology to track real-world outcomes. **Application Due Date:** June 27, 2019

[RFA-HD-20-005 \(R01\)](#) – clinical trial optional

Research Project Grants in Pediatric Rehabilitation

This FOA seeks to increase the number of researchers and projects in pediatric rehabilitation. Please refer to the FOA for research topics of interest. Research areas with large current research investments will be given low priority. Applicants are encouraged to review the NIH Reporter for existing research studies in pediatric rehabilitation.

Application Due Date: June 27, 2019

[RFA-CA-19-035 \(R01\)](#) – clinical trial required

Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care

This FOA solicits applications that develop and test models of care for adult survivors of cancer who are transitioning from active treatment to follow-up care. Through this FOA, the NCI intends to support multi-level interventions that enhance communication, collaboration, and coordination among oncology and non-oncology providers to improve cancer survivor outcomes. **Application Due Date:** June 28, 2019

July Due Dates

[RFA-AI-19-022 \(R01\)](#) – clinical trial optional

U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS)

These FOAs will establish Phase 2 of the U.S.-South Africa research program. The intent is to foster stimulate, and/or expand basic, translational, behavioral and applied research that will advance scientific discovery and engage U.S. and South African researchers working collaboratively in the areas of HIV/AIDS and HIV/AIDS-associated malignancies. U.S. and South African investigators working in partnership will prepare and submit a single joint application.

Application Due Date: July 26, 2019

[RFA-DA-20-017 \(R41/R42\)](#); [RFA-DA-20-018 \(R43/R44\)](#) – clinical trial optional

Digital Health Technologies to Address the Social Determinants of Health in context of Substance Use Disorders (SUD)

These FOAs solicit research applications for commercializable, digital health-based products that aim at positively affecting the fundamental social and environmental conditions that are risk factors for the populations affected by the use of drugs, including opioids. **Application Due Dates:** July 29, 2019

[RFA-ES-19-009 \(R43/R44\)](#) clinical trial not allowed

SBIR E-Learning for HAZMAT and Emergency Response

This FOA encourages applications that further the development of Advanced Technology Training (ATT) products for: the health and safety training of hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biosafety response, infectious disease training and cleanup; emergency responders in disasters and resiliency training; and for ATT tools to assist in research into the acute and long-term health effects of environmental disasters. **Application Due Date:** July 31, 2019

August Due Dates

[RFA-CA-19-032 \(R01\)](#) – clinical trial optional

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Please refer to the FOA for the six PQs. **Application Due Date:** August 1, 2019

[RFA-RM-19-006 \(DP2\)](#) – clinical trial optional

NIH Directors New Innovator Award Program

This program is designed to support unusually creative investigators with highly innovative research ideas at an early stage of their career when they may lack the preliminary data required for an R01 grant application. The emphasis is on innovation and creativity; preliminary data are not required but may be included. The review process emphasizes the individual's creativity, the innovativeness of the research approaches, and the potential of the project, if successful, to have a significant impact on an important biomedical or behavioral research problem.

Application Due Date: August 26, 2019

September Due Dates

[RFA-MH-20-120 \(R01\)](#) – clinical trial not allowed

BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data

This FOA encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be held in one of the funded BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or novel analytic methods, data science techniques, and machine learning approaches.

Application Due Date: September 6, 2019

[RFA-RM-19-005 \(DP1\)](#) – clinical trial optional

NIH Directors Pioneer Award Program

This award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. The potential for impact on human health may be near term (clinical or translational research) or long term (basic research). The paramount features of the research proposed must be innovation and magnitude of potential impact. **Application Due Date:** September 9, 2019

[RFA-RM-19-008 \(DP5\)](#) – clinical trial optional

NIH Directors Early Independence Awards

This award supports exceptional investigators who wish to pursue independent research essentially after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

Application Due Date: September 13, 2019

[RFA-RM-19-007 \(R01\)](#) – clinical trial optional

NIH Directors Transformative Research Awards

This Award supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this FOA.

Application Due Date: September 20, 2019

[RFA-CA-19-019 \(R21\)](#) – clinical trial not allowed

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research

The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Application Due Dates: September 27, 2019

[RFA-CA-19-020 \(R33\)](#) – clinical trial not allowed

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research

This FOA solicits applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. **Application Due Dates:** September 27, 2019

[RFA-CA-19-021 \(R21\)](#) – clinical trial not allowed

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research

This FOA solicits applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions.

Application Due Dates: September 27, 2019

[RFA-CA-19-022 \(R33\)](#) – clinical trial not allowed

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research

This FOA solicits applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Application Due Dates: September 27, 2019

October Due Dates

[RFA-HL-17-022 \(R21\)](#)

Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research

This FOA will support meritorious exploratory research relevant to the [NHLBI mission](#) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository, thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals. **Application Due Dates:** October 17, 2019

[RFA-NS-19-031 \(P50\)](#) – clinical trial optional

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)

These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide outstanding environments for the training of new researchers capable of addressing high priority research objectives in the muscular dystrophies.

Application Due Date: October 31, 2019

November Due Dates

[RFA-DA-20-013 \(R01\)](#) – clinical trial optional

PrEP for HIV Prevention among Substance Using Populations

NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Only one clinical trial has evaluated PrEP among people who inject drugs and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. **Application Due Date:** November 8, 2019

[RFA-AI-19-045 \(UM1\)](#) – clinical trial required

HIV/AIDS Clinical Trials Units

Applications are solicited for Clinical Trials Units to provide scientific and administrative expertise as well as the infrastructure to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks. Clinical Trials Units will participate in the development of trials and provide clinical sites, local laboratory capacity, and pharmacy support for two or more HIV/AIDS Clinical Trials Networks. **Application Due Date:** November 18, 2019

Multiple Due Dates

[RFA-HL-19-016 \(R43\)](#) – clinical trial not allowed

Technologies for Healthy Independent Living for Heart, Lung, Blood and Sleep Disorders

This FOA seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. **Application Due Dates:** June 10, 2019; June 10, 2020

[RFA-CA-19-039 \(U01\)](#) – clinical trial optional

Early-Stage Development of Informatics Technologies for Cancer Research and Management

This FOA invites applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum and focuses on early-stage development from prototyping to hardening and adaptation. **Application Due Dates:** June 11, 2019; November 20, 2019

[RFA-CA-19-040 \(U24\)](#) – clinical trial optional

Advanced Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.

Application Due Dates: June 11, 2019; November 20, 2019

[RFA-CA-19-041 \(U24\)](#) – clinical trial optional

Sustained Support for Informatics Technologies for Cancer Research and Management

The focus of this FOA is on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by the companion FOAs. **Application Due Dates:** June 11, 2019; November 20, 2019

[RFA-CA-19-034 \(P20\)](#) – clinical trial optional

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020

[RFA-ES-16-005 \(R21\)](#)

Mechanism for Time-Sensitive Opportunities in Environmental Health Sciences

This FOA supports environmental health research in which an unpredictable event provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation is to understand the consequences of natural and man-made disasters or emerging environmental public health threats in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding (substantially shorter than the typical NIH grant review/award cycle) in order for the research question to be addressed and swiftly implemented. **Application Due Dates:** July 1, 2019, August 1, 2019; September 3, 2019

[RFA-NS-18-043 \(R01\)](#); [RFA-NS-18-042 \(R21\)](#) – clinical trial not allowed

Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment

These FOAs promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. **Application Due Dates:** July 11, 2019; November 12, 2019

[RFA-OD-18-005 \(K01\)](#) – clinical trial not allowed; [RFA-OD-18-006 \(K01\)](#) – clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

These FOAs provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Application Due Dates:** July 19, 2019, November 8, 2019

[RFA-OD-18-007 \(K99/R00\)](#) – clinical trial not allowed; [RFA-OD-18-008 \(K99/R00\)](#) – clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

The purpose of this award is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. **Application Due Dates:** July 19, 2019, November 8, 2019

[RFA-HL-19-023 \(T32\)](#) – clinical trial not allowed

T32 Training Program for Institutions that Promote Diversity

This program supports predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders.

Application Due Dates: September 4, 2019; February 26, 2020; September 4, 2020; February 26, 2021

[RFA-HL-19-024 \(R25\)](#) – clinical trial not allowed

Short-Term Research Education Program to Increase Diversity in Health-Related Research

This program supports educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. **Application Due Dates:** September 10, 2019, February 26, 2020, September 10, 2020, February 26, 2021

[RFA-DA-19-019 \(R43/R44\)](#); [RFA-DA-19-020 \(R41/R42\)](#) – clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency.

Application Due Dates: September 8, 2019, April 9, 2020, September 8, 2020, April 9, 2021, September 8, 2021

[RFA-HL-20-003 \(UG3/UH3\)](#) – clinical trial optional

[RFA-HL-20-004 \(U24\)](#) – clinical trial not allowed

Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR)

The UG3/UH3 invites applications for projects that propose to test late-stage (T4) implementation research strategies for optimally and sustainably delivering proven-effective, evidence-based multi-level interventions to reduce or eliminate cardiovascular and/or pulmonary health disparities, and that promote and improve population health in high-burden communities. The U24 invites applications for a Research Coordinating Center (RCC) to support projects from the UG3/UH3. The RCC will coordinate activities across all of the DECIPHeR projects.

Application Due Date: October 1, 2019

[RFA-HL-19-025 \(K01\)](#) – clinical trial required; [RFA-HL-19-026 \(K01\)](#) – clinical trial not allowed

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

These FOAs are targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: October 10, 2019, February 11, 2020, October 9, 2020, February 11, 2021

NIH FUNDING OPPORTUNITIES

PROGRAM ANNOUNCEMENTS REVIEWED BY AN INSTITUTE (PAR)

[PAR-19-277 \(R21\)](#) – clinical trial optional

Exploratory Grants in Epidemiology

This FOA supports novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations.

Application Due Dates: June 7, 2019; October 8, 2019; June 8, 2020; October 8, 2020; June 8, 2021; October 8, 2021

[PAR-19-278 \(R21/R33\)](#) – clinical trial not allowed

Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders

This initiative supports projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies.

Application Due Dates: June 24, 2019, December 18, 2019, June 24, 2020, December 18, 2020, June 24, 2021, December 17, 2021

[PAR-19-251 \(R01\); PAR-19-252 \(R21\)](#) – clinical trial optional

Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention

These FOAs support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. **Application Due Dates:** July 2, 2019; November 6, 2019; July 2, 2020;

November 6, 2020; July 8, 2021; November 8, 2021

[PAR-19-258 \(R25\)](#) – clinical trial not allowed

NIDA Research Education Program for Clinical Researchers and Clinicians

The over-arching goal of this Program is to support research education activities that enhance the knowledge of substance use (SU) and substance use disorder (SUD) research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. **Application Due Dates:** July 22, 2019; July 22, 2020; July 22, 2021

[PAR-19-259 \(P50\)](#) – clinical trial optional

NIDA Research Center of Excellence Grant Program

A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field. The Research Centers: (1) will conduct drug abuse and addiction research in any area of NIDA's mission, (2) will have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) will serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields.

Application Due Dates: January 7, 2020; January 7, 2021; January 7, 2022

[PAR-19-274 \(R01\); PAR-19-275 \(R21\)](#) – clinical trial optional

[PAR-19-276 \(R03\)](#) – clinical trial not allowed

Dissemination and Implementation Research in Health

These FOAs support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. **Application Due Dates:** Standard dates apply; **Expiration Date:** May 8, 2022

NIH FUNDING OPPORTUNITIES

PROGRAM ANNOUNCEMENTS (PA)

The following opportunities have standard due dates unless noted otherwise:

Parent SBIR/STTR FOAs:

[PA-19-270 \(R41/R42\)](#) – clinical trial not allowed

[PA-19-271 \(R21/R42\)](#) – clinical trial required

Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications

Expiration Date: April 7, 2020

[PA-19-272 \(R43/R44\)](#) – clinical trial not allowed

[PA-19-273 \(R43/R44\)](#) – clinical trial required

Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications

Expiration Date: April 7, 2020

FUNDING OPPORTUNITIES : ADMINISTRATION FOR COMMUNITY LIVING

National Inst. on Disability, Independent Living, and Rehabilitation Research

[HHS-2019-ACL-NIDILRR DPGE 0354 \(Research\)](#)

[HHS-2019-ACL-NIDILRR-DPGE-0355 \(Development\)](#)

Disability and Rehabilitation Research Projects (DRRP): Assistive Technology to Promote Independence and Community Living

These FOAs support projects toward technology solutions to promote independence and community living outcomes of people with disabilities, with a particular emphasis on seniors with disabilities. **Application Due Dates:** June 17, 2019

[HHS-2019-ACL-NIDILRR-REGE-0343](#)

Rehabilitation Engineering Research Centers (RERCs) Program: RERC on Technologies to Enhance Independence and Community Living for People with Cognitive Impairments

This program supports advanced engineering research on and development of innovative technologies that are designed to solve particular rehabilitation problems or remove environmental barriers, with a focus on improving abilities of adults with cognitive impairment to perform daily activities in their choice of home, community, or workplace.

Application Due Date: July 15, 2019

FUNDING OPPORTUNITIES: U.S. DEPARTMENT OF DEFENSE

FY2019 Peer Reviewed Alzheimer's Research Programs

Military personnel and other individuals living with traumatic brain injury (TBI) face an increased risk for developing several long-term health problems. These include dementia, aggression, memory loss, depression, and symptoms similar to those of other neurological diseases. This FOA is devoted to 1) understanding the association between TBI and AD/ADRD; and 2) reducing the burden on affected individuals and caregivers. Applicants are encouraged to review the FOA for the FY19 focus areas. **Due Dates:** Pre-Application - June 26, 2019; Application Due Date - July 17, 2019

[W81XWH-19-PRARP-INCASA](#)

Innovations in Care and Support Award

This FOA supports innovative research that improves the quality of life and care for individuals living with the common symptoms of TBI and/or AD/ADRD and/or their families and care providers.

Funding Level I: supports early-career investigators within 3 years of their first independent faculty position. The total maximum award is \$225,000 direct costs for up to 3 years.

Funding Level II: supports PIs at or above the level of assistant professor. The total maximum award is \$500,000 for up to 3 years.

[W81XWH-19-PRARP-CSRA](#)

Convergence Science Research Award

This FOA supports innovative or novel efforts to generate research resources, tools, or research efforts for researchers and/or practitioners in health sciences.

Funding Level I: supports early-career investigators within 3 years of their first independent faculty position. The total maximum award is \$225,000 direct costs for up to 3 years.

Funding Level II: supports PIs at or above the level of assistant professor. The total maximum award is \$500,000 for up to 3 years.

[W81XWH-19-PRARP-RPA](#)

Research Partnership Award

This FOA intends to create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. In addition to supporting basic research, FY19 PRARP RPA applications proposing preclinical or pre-validation research are acceptable. The maximum award is \$1,300,000 total costs for up to 3 years.

FY2019 Peer Reviewed Orthopaedic Research Programs

The FY19 PRORP challenges the scientific community to address the most significant gaps in care for the leading burden of injury and for facilitating return to duty. The program intends to support innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from neuromusculoskeletal injuries (excluding spinal cord injuries) sustained during combat or combat-related activities. It is expected that research findings would also benefit the general population. Applications involving multidisciplinary collaborations among academia, industry, the military Services, the Department of Veterans Affairs (VA), and other Federal agencies are highly encouraged.

Due Dates: Pre-Application – June 26, 2019; Invited Application – September 18, 2019

[W81XWH-19-PRORP-ARA](#)

Applied Research Award

This FOA is focused on applied research, defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance, and/or emerging approaches and technologies. The maximum total award is \$750,000 for up to 3 years.

[W81XWH-19-PRORP-CTA](#)

Clinical Trial Award

This award supports the rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries or non-battle injuries that significantly impact unit readiness and return to duty/work rates. Applicants are encouraged to address how the proposed research will support patient care closer to the point of injury and/or allow patients to more quickly return to duty/work.

Funding Level 1 – all applications submitted are eligible for this funding level. The total award will not exceed \$2.5M for up to 4 years.

Funding Level 2 - Applications submitted to address the *Translation of Early Findings – Soft Tissue Trauma* Focus Area and include the Rehabilitation Option are eligible for Funding Level 2. The total award will not exceed \$3.0M for up to 4 years.

[W81XWH-19-PRORP-CTRA](#)

Clinical Translational Research Award

One goal of this award is to translate current and emerging techniques and interventions into the clinical space to better serve military patients closer to the point of injury and in a delayed evacuation scenario. The health, functional abilities, and quality of life of individuals who have sustained an orthopaedic injury should be considered. Another goal is to identify the most effective diagnosis, treatment, rehabilitation, and prevention options available to support critical decision-making for patients, clinicians, other caregivers, and policymakers. The maximum total award is \$2M for up to 4 years.

congratulations to our Graduates!!



“You are educated. Your certification is in your degree. You may think of it as the ticket to the good life. Let me ask you to think of an alternative. Think of it as your ticket to change the world.”

Tom Brokaw, (1940-), Television Journalist and Author

